Brought to you by 
AutoCyte, NeoPath merge in $101mm stock swap
17 Aug 1999
Executive Summary
Yielding what industry analysts deem to be around a 50% share of the US Pap smear market, cervical cell screening technology company AutoCyte will acquire automated Pap smear developer NeoPath in a stock swap valued at about $101mm, based on AutoCyte's $7.35 pre-announcement 10-day average trailing price. The price represents a (pr)46% premium to the $3.97 10-day trailing average for NeoPath common.
Deal Industry
- Biotechnology
-
In Vitro Diagnostics
- Cytology
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AutoCyte, NeoPath merge in $101mm stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice